Advertisement

Topics

Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Trea...

19:00 EST 9 Nov 2017 | BioSpace

The NDA submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up to one year.

Original Article: Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Trea...

NEXT ARTICLE

More From BioPortfolio on "Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Trea..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...